SFEBES2023 Poster Presentations Neuroendocrinology and Pituitary (74 abstracts)
Prevalence of cancer in a cohort of patients with prolactinoma compared to acromegaly
Iustin-Daniel Toma 1,2 , Raluca Trifanescu 1,2 , Ionela Baciu 1,2 , Nicoleta Baculescu 1,2 , Iulia Burcea 1,2 , Cristina Capatina 1,2 , Ramona Dobre 1,2 , Roxana Dusceac 2 , Simona Galoiu 1,2 , Dan Niculescu 1,2 , Serban Radian 1,2 & Catalina Poiana 1,2
1"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2"C. I. Parhon" National Institute of Endocrinology, Bucharest, Romania
Background: While growth hormone (GH) is involved in oncogenic transformation and IGF1 inhibits apoptosis, studies and case reports have shown an association between prolactin (PRL) and prostate cell proliferation, breast, gynecological, colorectal and hematopoietic cancer.
Aim: To compare the cancer rates in prolactinomas vs. acromegaly.
Methods: Retrospective study by analyzing the files of patients with acromegaly (ACM) and prolactinomas (PRM) who were followed-up within a tertiary endocrine center between 2018-2023. IGF1, GH and Prolactin were measured by chemiluminescence. Thyroid US, cytology exam by fine needle aspiration in suspicious nodules, colonoscopy, PAP, mammography were performed according to the latest guidelines as well as pathology exam in patients who underwent surgery. Patients with long distance between cancer and pituitary tumors (>5 years) were excluded.
Results: 161 patients had acromegaly (F=104, M= 57) and 95 had prolactinoma (F=46, M= 49; 68 macroadenomas and 27 microadenomas). Globally, cancer prevalence was 7.42% [n= 19, 15 cancers in acromegaly (9.32%) and 4 in prolactinomas (4.21%)]. In our prolactinoma group, 3 out of 4 cancers (bladder, breast and renal) had macroprolactinoma and only one cancer (endometrial cancer) had a microprolactinoma One out of 3 macroprolactinomas had underwent irradiation due to resistant prolactinoma. Macroprolactinomas who underwent irradiation did not have an increased risk in developing cancer in our cohort. (P= NS, chi-sq). Also, no statistical difference was found in cancer risk between ACM and PRL (P=NS, chi-sq), however patients with acromegaly are at a higher risk to develop thyroid nodules than those with prolactinomas (P= 0,02, chi-sq).
Conclusion: In our retrospective series, patients with GH excess had a higher incidence of thyroid nodules compared to those with prolactin excess. Irradiation in the prolactin group did not increase the risk to develop cancer, however larger and prospectives studies might clarify this aspect.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more